In medical imaging, techniques such as magnetic resonance imaging, contrast-enhanced
computerized tomography, and positron emission tomography (PET) are extensively …

Radiopharmaceuticals are essential components of nuclear medicine and serve as one of
the cornerstones of molecular imaging and precision medicine. They provide new means …

Purpose: Nectin-4 is an emerging biomarker for cancer diagnosis and therapy. Recently,
enfortumab vedotin (EV) was approved by the FDA as the first nectin-4 targeting antibody …

Radioisotope-labeled prostate-specific membrane antigen (PSMA) PET tracers have gained
popularity in diagnosing prostate cancer (PCa). This study aimed to improve the affinity and …

The efficient, large-scale synthesis of radiometallated radiopharmaceuticals represents an
emerging clinical need which, to date, is inherently limited by time consuming, sequential …

Nuclear medicine in China started in 1956 and, with the rapid development of the economy
and continuous breakthroughs in precision medicine, has made significant progress in …

Prostate specific membrane antigen positron emission tomography (PSMA PET) is an
excellent molecular imaging technique for prostate cancer. Currently, PSMA PET for patients …

With the flourishing development of precision medicine, theranostics, generally recognized
as the integration of diagnosis and treatment, has emerged as a prominent trend in clinical …

P137 is a novel oxalyldiaminopropionic acid-urea-based prostate-specific membrane
antigen (PSMA) targeting agent. This study compared the uptake patterns of 68Ga-P137 and …

Although PSMA PET/CT imaging has great potential for noninvasively detecting prostate
cancer (PCa), limitations exist for patients with low PSMA expression, caused by androgen …